托伐普坦纠正低钠血症导致渗透性脱髓鞘综合征1例并文献复习
A Case of Tolvaptan-Induced Osmotic Demyelination Syndrome Secondary to Correcting Hyponatremia: A Literature Review
DOI: 10.12677/ACM.2023.1371663, PDF,    科研立项经费支持
作者: 李 旭*, 张 亮*, 杨绍楠#, 宋敬卉#:青岛大学医学院,山东 青岛;青岛大学附属医院,山东 青岛;刘丽君:青岛大学附属医院,山东 青岛
关键词: 渗透性脱髓鞘综合征低钠血症小细胞肺癌托伐普坦Osmotic Demyelination Syndrome Hyponatremia Small Cell Lung Cancer Tolvaptan
摘要: 目的:报道托伐普坦纠正低钠血症导致渗透性脱髓鞘综合征1例,探讨托伐普坦会过快纠正低钠血症时会导致患者发生渗透性脱髓鞘综合征的可能性,以及渗透性脱髓鞘综合征的患者,其影像学改变往往迟于其临床表现。方法:我院收治1例服用托伐普坦后导致低钠血症被过快纠正进一步出现渗透性脱髓鞘综合征。结论:遵循指南推荐剂量服用托伐普坦,在纠正低钠血症后有出现渗透性脱髓鞘综合征的可能,以及对于这一类患者而言,神经影像学在早期诊断中与临床表现并不具备很好的相关性。
Abstract: Introduction: The purpose of this study is to examine the potential risk of tolvaptan-induced os-motic demyelination syndrome in patients when correcting hyponatremia too rapidly. Additionally, we aim to evaluate the correlation between the timing of radiological changes and clinical manifes-tations in patients with osmotic demyelination syndrome. Methods: A single case of a patient who developed osmotic demyelination syndrome as a consequence of rapid correction of hyponatremia caused by tolvaptan treatment is presented. The patient’s clinical history, laboratory data, imaging findings, and clinical course are described. Conclusion: Our findings suggest that there is a possibil-ity of osmotic demyelination syndrome occurring in patients when correcting hyponatremia too rapidly with tolvaptan. Furthermore, the radiological changes in patients with osmotic demye-lination syndrome often lag behind their clinical manifestations, emphasizing the importance of clinical assessment and monitoring in early diagnosis and management of this condition.
文章引用:李旭, 张亮, 刘丽君, 杨绍楠, 宋敬卉. 托伐普坦纠正低钠血症导致渗透性脱髓鞘综合征1例并文献复习[J]. 临床医学进展, 2023, 13(7): 11870-11875. https://doi.org/10.12677/ACM.2023.1371663

参考文献

[1] Sterns, R.H. (2015) Disorders of Plasma Sodium—Causes, Consequences, and Correction. The New England Journal of Medicine, 372, 55-65. [Google Scholar] [CrossRef
[2] Raspotnig, M., Vedeler, C. and Storstein, A. (2015) Paraneoplastic Neurological Syndromes in Lung Cancer Patients with or without Onconeural Antibodies. Journal of the Neurological Sciences, 348, 41-45. [Google Scholar] [CrossRef] [PubMed]
[3] Humayun, M.A. and Cranston, I.C. (2017) In-Patient Tolvaptan Use in SIADH: Care Audit, Therapy Observation and Outcome Analysis. BMC Endocrine Disorders, 17, Article No. 69. [Google Scholar] [CrossRef] [PubMed]
[4] Marroncini, G., et al. (2021) Low Sodium and Tolvaptan Have Opposite Effects in Human Small Cell Lung Cancer Cells. Molecular and Cellular Endocrinology, 537, Article ID: 111419. [Google Scholar] [CrossRef] [PubMed]
[5] Schrier, R.W., et al. (2006) Tolvaptan, a Selective Oral Vasopressin V2-Receptor Antagonist, for Hyponatremia. The New England Journal of Medicine, 355, 2099-2112. [Google Scholar] [CrossRef
[6] Martin, R.J. (2004) Central Pontine and Extrapontine Myelinolysis: The Osmotic Demyelination Syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 75, iii22-iii28. [Google Scholar] [CrossRef] [PubMed]
[7] Adrogue, H.J. and Madias, N.E. (2000) Hyponatremia. The New England Journal of Medicine, 342, 1581-1589. [Google Scholar] [CrossRef
[8] Georgy, V., Mullhi, D. and Jones, A.F. (2007) Central Pon-tine Myelinolysis Following “Optimal” Rate of Correction of Hyponatraemia with a Good Clinical Outcome. Annals of Clinical Biochemistry, 44, 488-490. [Google Scholar] [CrossRef] [PubMed]
[9] Kleinschmidt-Demasters, B.K., Rojiani, A.M. and Filley, C.M. (2006) Central and Extrapontine Myelinolysis: Then ... and Now. Journal of Neuropathology & Experimental Neurology, 65, 1-11. [Google Scholar] [CrossRef] [PubMed]
[10] Chang, Y., An, D.-H., Xing, Y. and Qi, X. (2012) Central Pontine and Extrapontine Myelinolysis Associated with Acute Hepatic Dysfunction. Neurological Sciences, 33, 673-676. [Google Scholar] [CrossRef] [PubMed]
[11] Lampl, C. and Yazdi, K. (2002) Central Pontine Mye-linolysis. European Neurology, 47, 3-10. [Google Scholar] [CrossRef] [PubMed]
[12] Burcar, P.J., Norenberg, M.D. and Yarnell, P.R. (1977) Hyponatremia and Central Pontine Myelinolysis. Neurology, 27, 223-226. [Google Scholar] [CrossRef
[13] Lambeck, J., Hieber, M., Dreßing, A. and Niesen, W.D. (2019) Central Pontine Myelinosis and Osmotic Demyelination Syndrome. Deutsches Ärzteblatt International, 116, 600-606. [Google Scholar] [CrossRef] [PubMed]
[14] Forster, A., et al. (2013) Value of Diffusion-Weighted Imaging in Central Pontine and Extrapontine Myelinolysis. Neuroradiology, 55, 49-56. [Google Scholar] [CrossRef] [PubMed]
[15] Chua, G.C., Sitoh, Y.Y., Lim, C.C., Chua, H.C. and Ng, P.Y. (2002) MRI Findings in Osmotic Myelinolysis. Clinical Radiology, 57, 800-806. [Google Scholar] [CrossRef] [PubMed]
[16] Takagi, H., et al. (2014) Minocycline Prevents Osmotic Demyelination Associated with Aquaresis. Kidney International, 86, 954-964. [Google Scholar] [CrossRef] [PubMed]
[17] Berl, T., et al. (2010) Oral Tolvaptan Is Safe and Effective in Chronic Hyponatremia. Journal of the American Society of Nephrology, 21, 705-712. [Google Scholar] [CrossRef
[18] Doggrell, S.A. (2004) Tolvaptan (Otsuka). Current Opinion in Investigational Drugs, 5, 977-983.
[19] Ren, P. and Yang, Q. (2021) The Role of Tolvaptan in Managing Hyponatremia in Small Cell Lung Cancer Patients with SIADH: A Retrospective Study of 23 Cases. Translational Can-cer Research, 10, 1229-1237. [Google Scholar] [CrossRef] [PubMed]
[20] Shoaf, S.E., Bricmont, P. and Dandurand, A. (2017) Low-Dose Tolvaptan PK/PD: Comparison of Patients with Hyponatremia Due to Syndrome of Inappropriate Antidiuretic Hormone Secretion to Healthy Adults. European Journal of Clinical Pharmacology, 73, 1399-1408. [Google Scholar] [CrossRef] [PubMed]
[21] Kim, Y., Lee, N., Lee, K.E. and Gwak, H.S. (2020) Risk Factors for Sodium Overcorrection in Non-Hypovolemic Hyponatremia Patients Treated with Tolvaptan. European Journal of Clinical Pharmacology, 76, 723-729. [Google Scholar] [CrossRef] [PubMed]
[22] Kleindienst, A., et al. (2020) Tolvaptan versus Fluid Restriction in the Treatment of Hyponatremia Resulting from SIADH Following Pituitary Surgery. Journal of the Endocrine Society, 4, bvaa068. [Google Scholar] [CrossRef] [PubMed]
[23] Zmily, H.D., Daifallah, S. and Ghali, J.K. (2011) Tolvaptan, Hypo-natremia, and Heart Failure. International Journal of Nephrology and Renovascular Disease, 4, 57-71. [Google Scholar] [CrossRef